目的初步考察汉族人有机阴离子转运多肽1B1(OATP1B1)的遗传多态性及其对普伐他汀药动学的影响。方法考察180名汉族健康受试者SLCO1B1(OATP1B1的编码基因)的常见单体型(SLCO1B1*1a,SLCO1B1*1b,SLCO1B1*5及SLCO1B1*15),从中选择18名自愿参加且基因型为SLCO1B1*1b/*1b,SLCO1B1*1a/*15,SLCO1B1*1b/*15或SLCO1B1*15/*15的受试者入组药动学研究。分别在给药前及给予40 mg普伐他汀后0.33,0.67,1,1.5,2,3,4,5,6,8 h采集受试者血样至肝素抗凝管中。血浆普伐他汀浓度采用HPLC-UV测定。药动学参数应用WinNonlin 1.5软件中的非房室模型计算。SLCO1B1*1b纯合子组受试者(n=9)和SLCO1B1*15杂合子组受试者(n=8)药动学参数的统计学差异应用SPSS 10.0软件中的Mann-Whitney U检验评价。结果180名汉族人单体型SLCO1B1*1a,SLCO1B1*1b和SLCO1B1*15的发生频率分别为0.294,0.614和0.092,未发现单体型SLCO1B1*5;基因型SLCO1B1*1a/*1a,SLCO1B1*1a/*1b,SLCO1B1*1b/*1b,SLCO1B1*1a/*15,SLCO1B1*1b/*15及SLCO1B1*15/*15的发生频率分别为0.078,0.372,0.372,0.061,0.111及0.006。SLCO1B1*1b纯合子组受试者(n=9)和SLCO1B1*15杂合子组受试者(n=8)的ρmax分别为(116.06±46.22)和(173.36±36.23)μg·L-1,二者存在统计学差异(P=0.011<0.05)。2组受试者的其他药动学参数,如AUC0-8 h(P=0.093>0.05),tmax(P=0.139>0.05),t1/2(P=0.093>0.05)及CL/F(P=0.114>0.05)无统计学差异。值得注意的是,SLCO1B1*15纯合子(n=1)的ρmax和AUC0-8 h在所有受试者中最高,分别为401.76μg·L-1和660.05μg·h·L-1;CL/F最低,为59.60 L·h-1。结论180名汉族人OATP1B1存在遗传多态性,最常见的单体型为SLCO1B1*1b。OATP1B1遗传多态性会对普伐他汀药动学产生影响。服用普伐他汀后,携带SLCO1B1*15的受试者,尤其是SLCO1B1*15纯合子受试者的血药浓度显著高于其他受试者。
Abstract
OBJECTIVE To investigate the genetic polymorphism of organic anion transporting polypeptide 1B1(OATP1B1) in Han population and the effects of the genetic polymorphism on the pharmacokinetic profile of pravastatin.METHODS The common haplotypes of SLCO1B1(the coding gene of OATP1B1),which were reported as SLCO1B1 1a,SLCO1B1 1b,SLCO1B1 5 and SLCO1B1 15,were determined in 180 Han healthy subjects,18 of whom with the genotypes of SLCO1B1 1b/ 1b,SLCO1B1 1a/ 15,SLCO1B1 1b/ 15 or SLCO1B1 15/ 15 were chosen and grouped in the pharmacokinetic study.Serial blood samples were collected into heparinized tubes before dosing and at 0.33,0.67,1,1.5,2,3,4,5,6 and 8 h after 40 mg pravastatin administration.The plasma pravastatin concentrations were assayed by HPLC-UV method.The pharmacokinetic parameters were assessed by a noncompartment model using WinNonlin 1.5 software.The statistical differences of the pharmacokinetic parameters between the SLCO1B1 1b homozygous carriers(n=9) and the SLCO1B1 15 heterozygous carriers(n=8) were determined by Mann-Whitney U test using SPSS10.0 software.RESULTS The frequencies of SLCO1B1 1a,SLCO1B1 1b and SLCO1B1 15 were 0.294,0.614,0.092,respectively.However,no SLCO1B1 5 was found.The frequencies of SLCO1B1 1a/ 1a,SLCO1B1 1a/ 1b,SLCO1B1 1b/ 1b,SLCO1B1 1a/ 15,SLCO1B1 1b/ 15 and SLCO1B1 15/ 15 were 0.078,0.372,0.372,0.061,0.111 and 0.006,respectively.It was showed that the values of ρmax were(116.06±46.22) and(173.36±36.23)μg·L-1 in the SLCO1B1 1b homozygous carriers and the SLCO1B1 15 heterozygous carriers,respectively,with significant difference(P=0.011<0.05).Other pharmacokinetic parameters,such as AUC0-8 h(P=0.093>0.05),tmax(P=0.139>0.05),t1/2(P=0.093>0.05) and CL/F(P=0.114>0.05),had no significant differences between the two study groups.Strikingly,the ρmax and AUC0-8 h in the SLCO1B1 15 homozygous carrier(n=1),which were 401.76 μg·L-1 and 660.05 μg·h·L-1,respectively,were the highest,the CL/F which was 59.60 L·h-1 was the lowest among all participants.CONCLUSION There was genetic polymorphism of OATP1B1 in Han population,and the most common haplotype was SLCO1B1 1b.The pharmacokinetic profile of pravastatin was affected by the genetic polymorphism of OATP1B1.After pravastatin administration,higher concentrations were seen in the SLCO1B1 15 carriers,especially the SLCO1B1 15 homozygous carrier.
关键词
普伐他汀 /
OATP1B1 /
遗传多态性 /
药动学
{{custom_keyword}} /
Key words
pravastatin /
OATP1B1 /
genetic polymorphism /
pharmacokinetics
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TIRONA R G，LEAKE B F，MERINO G，et al. Polymorphisms in OATP-C：identification of multiple allelic variants associated with altered transport activity among European- and African-Americans[J] . J Biol Chem，2001，276(38)：35669-35675.
[2] NOZAWA T，NAKAJIMA M，TAMAI I，et al. Genetic polym- orphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9)：allele frequencies in the Japanese population and functional analysis[J] . J Pharmacol Exp Ther，2002，302(2)：804-813.
[3] MICHALSKI C，CUI Y，NIES A T，et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter[J] . J Biol Chem，2002，277(45)：43058-43063.
[4] NISHIZATO Y，IEIRI I，SUZUKI H，et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes：consequences for pravastatin pharmacokinetics[J] . Clin Pharmacol Ther，2003，73(6)：554-565.
[5] MWINYI J，JOHNE A，BAUER S，et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics[J] . Clin Pharmacol Ther，2004，75(5)：415-421.
[6] DENG M，XU H Y，LIU H C，et al. Study on bioequivalence of pravastatin sodium tablets in healthy volunteers [J] . Chin Pharm J（中国药学杂志），2005，40(6)：451-453.
[7] OGAWA K，HASEGAWA S，UDAKA Y，et al. Individual diff- erence in the pharmacokinetics of a drug，pravastatin，in healthy subjects[J] . J Clin Pharmacol，2003，43(11)：1268-1273.
[8] NIEMI M，NEUVONEN P J，HOFMANN U，et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17[J] . Pharmacogenetics Genomics，2005，15(5)：303-309.
[9] HAMILTON-CRAIG I. Statin-associated myopathy[J] . Med J Aust，2001，175(9)：486-489.
[10] NAKAI D，NAKAGOMI R，FURUTA Y，et al. Human liver-specific organic anion transporter，LST-1，mediates uptake of pravastatin by human hepatocytes[J] . J Pharmacol Exp Ther，2001，297 (3)：861-867.
[11] KAMEYAMA Y，YAMASHITA K，KOBAYASHI K，et al. Func- tional characterization of SLCO1B1 (OATP-C) variants，SLCO1B1*5，SLCO1B1*15 and SLCO1B1*15+C1007G，by using transient expression systems of HeLa and HEK293 cells[J] . Pharmacogenet Genomics，2005，15(7)：513-522.
[12] NOZAWA T，MINAMI H，SUGIURA S，et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite，7-ethyl-10-hydroxycamptothecin：in vitro evidence and effect of single nucleotide polymorphisms[J] . Drug Metab Dispos，2005，33(3)：434-439.
[13] IWAI M，SUZUKI H，IEIRI I，et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C)[J] . Pharmacogenetics，2004，14(11)：749-757.
[14] PAN H Y，WACLAWSKI A P，FUNKE P T，et al. Pharm- acokinetics of pravastatin in elderly versus young men and women[J] . Ann Pharmacother，1993，27(9)：1029-1033.
[15] NIEMI M，SCHAEFFELER E，LANG T，et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C，SLCO1B1) [J] . Pharmacogenetics，2004，14(7)：429-440.
[16] PASANEN M K，BACKMAN J T，NEUVONEN P J，et al. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a finnish population finnish population[J] . Eur J Clin Pharmacol，2006，62(6)：409-415.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
